- The FDA published Provention Bio Inc’s PRVB teplizumab-related briefing documents ahead of an Advisory Committee meeting scheduled for May 27 (Thursday).
- The agency sounded a relatively positive tone on safety and efficacy after identifying deficiencies that preclude discussion of labeling and post-marketing requirements.
- The company seeks approval for teplizumab for the delay of progression to clinical type 1 diabetes (T1D) in at-risk patients.
- The approval could make teplizumab the first disease-modifying therapy that preserves beta-cell function for patients with stage 2 of the disease who are at risk of progressing to stage 3 clinical T1D, stated the document.
- In the pivotal TN-10 study, a single 14-day course of teplizumab was well tolerated and resulted in a 2-year delay in the progression to Stage 3 insulin-dependent T1D.
- “The totality of the efficacy and safety data strongly supports the positive benefit/risk of teplizumab for the delay of progression to Stage 3 clinical T1D in at-risk patients with pre-symptomatic Stage 2 T1D,” according to the FDA document.
- In April, the FDA identified deficiencies expressing concerns over teplizumab pharmacokinetics data and comparability when Lilly first put teplizumab into clinical trials.
- Price Action: PRVB shares are up 27.1% at $10.14 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in